Hyperhidrosis (Excessive Sweating) [2026]: Causes, Triggers, and Prescription Treatment Options

Last updated: October 21, 2026 Reviewed by PrescribedGlow Editorial Team, Editorial

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. Our editorial opinions are our own.

Hyperhidrosis is a chronic medical disorder characterized by excessive, unpredictable sweating that exceeds the physiological requirements of body temperature regulation. Driven by overactive sympathetic nerve signaling to eccrine sweat glands rather than gland size or quantity, it is effectively managed with prescription aluminum chloride, targeted topical anticholinergics (Qbrexza, Sofdra), and oral antimuscarinics like glycopyrrolate.

Affiliate Disclosure: PrescribedGlow is supported by our readers. When you purchase prescription treatments through links on our site, we may earn an affiliate commission at no extra cost to you.

What is the difference between primary and secondary hyperhidrosis?

Primary focal hyperhidrosis is an idiopathic neurogenic disorder that causes bilateral, symmetrical sweating restricted to specific high-density eccrine zones—most commonly the underarms, palms, soles, and craniofacial region. Secondary generalized hyperhidrosis arises later in adulthood as a consequence of an underlying systemic illness, hormonal shift, or pharmaceutical side effect, causing widespread body sweating.

According to a national epidemiological study by Doolittle et al. in the Archives of Dermatological Research (PMID: 27744497), primary focal hyperhidrosis is the dominant presentation, most commonly affecting the axillae, palms, and soles in a bilateral, symmetrical pattern, as distinct from the generalized, often nocturnal sweating seen in secondary hyperhidrosis.

Clinical Feature Primary Focal Hyperhidrosis Secondary Generalized Hyperhidrosis
Root Mechanism Sympathetic nerve hyperactivity via acetylcholine Endocrine, metabolic, or drug-induced trigger
Age of Onset Childhood or adolescence (before age 25) Adulthood (typically after age 25)
Distribution Focal, bilateral, symmetrical (axillae, palms, soles) Generalized across large body surfaces
Night Sweats Rarely sweats during sleep Frequently causes drenching night sweats
Common Causes Genetic predisposition (30%–50% family history) Perimenopause, hyperthyroidism, SSRIs, diabetes

If excessive sweating begins abruptly in adulthood or causes drenching night sweats, clinicians screen for secondary triggers—such as thyroid dysfunction, SSRI antidepressants, or perimenopausal estrogen decline—before prescribing localized therapies.

What causes excessive sweating and triggers hyperhidrosis flare-ups?

Excessive sweating in primary hyperhidrosis occurs when the hypothalamic thermoregulatory center misfires, sending amplified autonomic signals down sympathetic nerve fibers to release acetylcholine onto eccrine sweat glands. Although the eccrine glands themselves are completely normal in number, size, and microscopic structure, this neurotransmitter surge triggers profuse perspiration without heat or exercise.

According to a national epidemiological study by Doolittle et al. in the Archives of Dermatological Research (PMID: 27744497), hyperhidrosis affects an estimated 4.8% of the U.S. population (approximately 15.3 million people), peaking at 8.8% among adults aged 18 to 39. Although 70% report severe sweating in at least one body area, only 51% have ever discussed their condition with a healthcare professional.

Common triggers that lower the sympathetic firing threshold include:

  • Emotional & Social Stress: Anticipatory anxiety activates the fight-or-flight cascade, instantaneously triggering palmar, plantar, and axillary glands.
  • Caffeine, Nicotine & Spicy Foods: Caffeine elevates central nervous system alertness, nicotine stimulates sympathetic ganglia, and capsaicin triggers reflex craniofacial sweating.
  • Hormonal Transitions: Fluctuating estradiol and progesterone during perimenopause or premenstrual phases destabilize hypothalamic temperature control.
  • Secondary Skin Complications: Chronic moisture macerates the skin barrier, predisposing intertriginous folds to Malassezia and bacterial folliculitis or aggravating painful nodules in hidradenitis suppurativa.

What is the best prescription treatment for hyperhidrosis?

The most effective prescription treatment for hyperhidrosis depends on the anatomical site and severity of perspiration. Localized underarm, palmar, or plantar sweating is managed with prescription 20% aluminum chloride hexahydrate (Drysol) or FDA-approved topical anticholinergics like glycopyrronium tosylate 2.4% cloths (Qbrexza) and sofpironium 12.45% gel (Sofdra), while multi-focal sweating responds to oral glycopyrrolate.

1. Prescription Aluminum Chloride Hexahydrate 20% (Drysol)

Applied to bone-dry skin at bedtime, 20% aluminum chloride hexahydrate diffuses into the terminal eccrine duct and forms a temporary keratin-aluminum plug. Because anhydrous alcohol solutions can provoke irritant contact dermatitis, patients wash the area in the morning and taper use to 1–2 nights weekly once dry.

2. Topical Anticholinergic Cloths: Glycopyrronium Tosylate 2.4% (Qbrexza)

Qbrexza is a pre-moistened once-daily cloth FDA-approved for primary axillary hyperhidrosis that blocks M3 muscarinic acetylcholine receptors on underarm sweat glands. In the pooled Phase III ATMOS-1 and ATMOS-2 trials led by Glaser et al. in the Journal of the American Academy of Dermatology (PMID: 30003988), 59.5% of Qbrexza patients achieved a $\ge$4-point improvement on the Axillary Sweating Daily Diary at Week 4 versus 27.6% using vehicle ($P < .001$), with an average gravimetric sweat reduction of -107.6 mg/5 min.

3. Retrometabolic Topical Gel: Sofpironium 12.45% (Sofdra)

The FDA approved Sofdra (sofpironium bromide 12.45% gel) on June 21, 2024, for primary axillary hyperhidrosis. It uses a hands-free metered applicator and a retrometabolic “soft drug” design that breaks down rapidly in the bloodstream to minimize systemic dry mouth. In its Phase III registration trials, Sofdra outperformed vehicle gel on the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) scale over six weeks, supporting its FDA approval (see Sofdra prescribing information for full trial data).

4. Systemic Oral Anticholinergics (Glycopyrrolate & Oxybutynin)

For palmoplantar, craniofacial, or multi-site sweating, dermatologists prescribe oral glycopyrrolate (1–2 mg once or twice daily) or oxybutynin (5–10 mg daily). Because glycopyrrolate’s polar quaternary structure restricts blood-brain barrier penetration, it rarely causes drowsiness. In a clinical study by Lee et al. in the Korean Journal of Pain (PMID: 22259713), 75.0% of primary hyperhidrosis patients taking oral glycopyrrolate achieved a statistically significant decrease in perspiration ($P < 0.001$).

Prescription Therapy Mechanism Target Area Key Clinical Consideration
Drysol (Aluminum Chloride 20%) Physical intraductal plug Underarms, palms, soles Apply to completely dry skin at bedtime
Qbrexza (Glycopyrronium 2.4%) Topical M3 receptor blocker cloth Underarms (axillary) Wash hands after wiping to avoid eye dilation
Sofdra (Sofpironium 12.45% Gel) Retrometabolic anticholinergic gel Underarms (axillary) Hands-free applicator; lower systemic dry mouth
Oral Glycopyrrolate (1–2 mg) Systemic antimuscarinic tablet Palms, soles, face, multi-site Take on an empty stomach for optimal absorption

Can you get prescription hyperhidrosis treatment online?

Yes, adult patients can obtain a clinical diagnosis and prescription treatment for hyperhidrosis through online teledermatology platforms. Licensed medical providers evaluate your symptom history via asynchronous intake forms, screen for secondary systemic red flags, and send prescriptions for 20% aluminum chloride, Qbrexza, or oral glycopyrrolate to your local pharmacy or mail-order service.

Given the Doolittle et al. finding (PMID: 27744497) that 49% of hyperhidrosis sufferers never consult a doctor in person, virtual care offers private access to prescription relief. Understanding how telehealth works helps you choose the right clinic:

  • Honeydew Care: A full-scope online dermatology clinic where providers prescribe and handle insurance prior authorizations for Qbrexza, Sofdra, Drysol, and oral glycopyrrolate routed to your local pharmacy (Honeydew Care). See our Honeydew Care review for details.
  • Winona & Alloy (For Secondary Menopausal Sweating): For women experiencing generalized night sweats and hot flashes driven by perimenopause, Winona and Alloy prescribe bioidentical hormone replacement therapy (HRT) to stabilize hypothalamic thermoregulation. Compare both in our Winona vs. Alloy comparison.

Frequently asked questions

What is the difference between primary and secondary hyperhidrosis? Primary focal hyperhidrosis is an inherited neurological condition causing symmetrical, localized sweating on the underarms, palms, soles, or face during waking hours without an underlying medical disease. Secondary generalized hyperhidrosis occurs across the entire body—including during sleep—as a direct symptom of an endocrine condition, menopause, infection, or medication side effect.

What causes excessive sweating even when you are not hot? Excessive sweating without heat or physical exertion is caused by hyperactive sympathetic nerve fibers releasing excess acetylcholine onto anatomically normal eccrine sweat glands. Emotional stress, social anxiety, caffeine, nicotine, spicy foods, and hormonal fluctuations lower the hypothalamic sweat threshold, triggering sudden focal perspiration even in cool, air-conditioned environments.

What is the best prescription treatment for hyperhidrosis? The most effective prescription treatment depends on the affected body area. Mild-to-moderate focal sweating responds well to prescription 20% aluminum chloride hexahydrate (Drysol). Primary underarm hyperhidrosis is effectively treated with targeted anticholinergic topicals like glycopyrronium tosylate 2.4% cloths (Qbrexza) or sofpironium 12.45% gel (Sofdra), while multi-site sweating responds to oral glycopyrrolate.

How do Qbrexza and Sofdra work for underarm sweating? Qbrexza (glycopyrronium tosylate 2.4% cloth) and Sofdra (sofpironium 12.45% topical gel) are targeted topical anticholinergics applied once daily to the underarms. Instead of physically plugging sweat ducts like aluminum salts, they competitively block muscarinic acetylcholine receptors directly on eccrine sweat glands, halting nerve-stimulated perspiration at the cellular level.

Can hyperhidrosis be cured permanently? Primary focal hyperhidrosis cannot be cured permanently with topical or oral medications because it stems from genetic autonomic nerve hyperactivity. However, daily prescription antiperspirants, topical anticholinergics, and oral medications effectively control symptoms long-term, while in-office microwave thermolysis (miraDry) can permanently destroy axillary eccrine glands.

Can you get prescription hyperhidrosis treatment online? Yes, asynchronous teledermatology platforms evaluate and prescribe hyperhidrosis treatments online. Licensed clinicians review your medical intake to rule out secondary systemic causes and electronically prescribe 20% aluminum chloride, Qbrexza wipes, or oral glycopyrrolate tablets to your local pharmacy or via direct mail-order delivery.

Bottom line

Hyperhidrosis is a common, biologically driven neurological condition—not a personal hygiene issue. Whether you deal with focal underarm sweating or multi-site palmoplantar perspiration, targeted prescription therapies—from nighttime 20% aluminum chloride and once-daily Qbrexza or Sofdra topicals to systemic oral glycopyrrolate—provide reliable clinical relief.

Consult with Honeydew Care for prescription hyperhidrosis treatment · Explore Winona for hormonal night sweats · Explore Alloy Women’s Health

To learn more about related conditions, read our guides on hidradenitis suppurativa, fungal and bacterial folliculitis, contact dermatitis, and estriol for menopausal skin aging, or check our Winona review and Alloy review.


Sources: PMID 27744497 · PMID 30003988 · PMID 22259713 · FDA approval of Sofdra (sofpironium bromide), June 21, 2024